Csl Limited

The University of Melbourne

Csl Limited, A.c.n.

Ian George Barr

Bruce Carter Ross

Elizabeth Ann Webb

Linda J Rothel

Dianna M Hocking

Michelle A Patterson

Catherine T Agius

Mai B Margetts

Eric Charles Reynolds

Nada Slakeski

Chao Guang Chen

Christopher Vincent Doidge

Adrian Lee

Michael John Kleinig

Elizabeth Pietrzykowski

William J Thiel

Charles Alexander Quinn

Fiona Jane Buck

Larissa Czajkowski

Mai Brigid Margetts

Linda Joy Rothel

Catherine Therese Agius

Michelle Anne Patterson

The present invention provides an antigenic composition, the composition comprising at least one recombinant protein. The recombinant protein comprises at least one epitope. The epitope is reactive with an antibody which is reactive with a polypeptide having the sequence set out in SEQ. ID. NO. 3 or SEQ. ID. NO. 5. The invention also provides methods and compositions for the production of the recombinant protein. Also provided are methods for the diagnosis, treatment and prevention ofinfection.

[object Object]

The present invention relates to isolatedpolypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.

The present invention relates to isolatedpolypeptides and nucleotides. The polypeptides include;

The present invention relates to solublepolypeptides derived from PG32 and PG33 and to polynucleotides encoding these polypeptides. Thepolypeptides and nucleotides can be used in compositions for use in raising an immune response in a subject againstand treating or preventing or reducing the severity of the condition known as periodontitis or in other conditions related to infection with

Porphyromonas gingivalis recombinant proteins and truncations

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS of or , or an immunogenic fragment thereof.

Antigenic preparation for treatment or prevention of helicobacter infection

Single dose vaccination system

Growing community of inventors

Templestowe, Australia

Ian George Barr